New hope for stroke patients: drug may restore brain function hours later
NCT ID NCT07617870
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called pro-urokinase in people who have had a stroke in the back part of the brain (posterior circulation) and can be treated within 4.5 to 24 hours after symptoms start. About 586 participants will receive either the drug or a placebo, along with standard aspirin therapy. The goal is to see if the drug helps more people achieve a good recovery (minimal or no disability) at 90 days, compared to standard care alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human prourokinase (rhPro-UK)
What this could lead to
If successful, this could provide a new treatment option for certain stroke patients who are not eligible for clot removal, potentially improving recovery and reducing disability.
What could go wrong
This is an early-stage Phase 3 trial with 586 participants, so results may not apply to all stroke patients. The drug also carries bleeding risks, which could limit its safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Neurology, the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••